Thor Medical ASA - Asset Resilience Ratio

Latest as of December 2024: 29.78%

Thor Medical ASA (TRMED) has an Asset Resilience Ratio of 29.78% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Nkr123.39 Million

≈ $12.98 Million USD Cash + Short-term Investments

Total Assets

Nkr414.40 Million

≈ $43.61 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2020–2024)

This chart shows how Thor Medical ASA's Asset Resilience Ratio has changed over time. Check TRMED strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Thor Medical ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Thor Medical ASA.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Nkr123.39 Million	29.78%
Short-term Investments	Nkr0.00	0%
Total Liquid Assets	Nkr123.39 Million	29.78%

Asset Resilience Insights

Very High Liquidity: Thor Medical ASA maintains exceptional liquid asset reserves at 29.78% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Thor Medical ASA Industry Peers by Asset Resilience Ratio

Compare Thor Medical ASA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Akero Therapeutics Inc NASDAQ:AKRO	Biotechnology	55.87%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Zealand Pharma A/S CO:ZEAL	Biotechnology	63.98%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Immunitybio Inc NASDAQ:IBRX	Biotechnology	38.07%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for Thor Medical ASA (2020–2024)

The table below shows the annual Asset Resilience Ratio data for Thor Medical ASA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.00%	Nkr1.00K ≈ $105.23	Nkr414.40 Million ≈ $43.61 Million	-12.77pp
2023-12-31	12.77%	Nkr42.25 Million ≈ $4.45 Million	Nkr330.83 Million ≈ $34.81 Million	-77.26pp
2022-12-31	90.03%	Nkr98.72 Million ≈ $10.39 Million	Nkr109.64 Million ≈ $11.54 Million	-3.57pp
2021-12-31	93.61%	Nkr277.71 Million ≈ $29.22 Million	Nkr296.67 Million ≈ $31.22 Million	+0.17pp
2020-12-31	93.44%	Nkr293.98 Million ≈ $30.93 Million	Nkr314.61 Million ≈ $33.11 Million	--

pp = percentage points

About Thor Medical ASA

OL:TRMED Norway Biotechnology

Market Cap

$215.82 Million

Nkr2.05 Billion NOK

Market Cap Rank

#16208 Global

#131 in Norway

Share Price

Nkr5.79

Change (1 day)

+28.10%

52-Week Range

Nkr2.38 - Nkr5.79

All Time High

Nkr121.16